Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics


Hitesh

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a definitive agreement to divest Sunosi® (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA), to Axsome Therapeutics (Nasdaq: […]

Innovent and Lilly Expand Strategic Partnership in Oncology


Hitesh

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (“Lilly”,NYSE: LLY) today announced that in light of both parties’ shared commitment to continue bringing innovative medicines […]

Triastek and Siemens announce strategic collaboration to accelerate the digital transformation of the pharmaceutical industry


Hitesh

Triastek, Inc. and Siemens Ltd. have signed a strategic collaboration agreement in China to provide digital technologies to the global pharmaceutical industry. The combination of Triastek’s cutting-edge digital pharmaceutical and 3D printing technologies and Siemens’ global leadership in automation and digitization is expected to lead to innovative and transformative solutions […]